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The addition of ribavirin to alpha interferon therapy significantly increases response rates for patients with
chronic hepatitis C virus (HCV) infection, but ribavirin’s antiviral mechanisms are unknown. Ribavirin has
been suggested to have mutagenic potential in vitro that would lead to “error catastrophe,” i.e., the generation
of nonviable viral quasispecies due to the increment in the number of mutant genomes, which prevents the
transmission of meaningful genetic information. We used extensive sequence-based analysis of two indepen-
dent genomic regions in order to test in vivo the hypothesis that ribavirin administration accelerates the
accumulation of mutations in the viral genome and that this acceleration occurs only when HCV replication
is profoundly inhibited by coadministered alpha interferon. The rate of variation of the consensus sequence,
the frequency of mutation, the error generation rate, and the between-sample genetic distance were measured
for patients receiving ribavirin monotherapy, a combination of alpha interferon three times per week plus
ribavirin, or a combination of alpha interferon daily plus ribavirin. Ribavirin monotherapy did not increase the
rate of variation of the consensus sequence, the mutation frequency, the error generation rate, or the between-
sample genetic distance. The accumulation of nucleotide substitutions did not accelerate, relative to the
pretreatment period, during combination therapy with ribavirin and alpha interferon, even when viral repli-
cation was profoundly inhibited by alpha interferon. This study strongly undermines the hypothesis whereby
ribavirin acts as an HCV mutagen in vivo.
Hepatitis C virus (HCV) infection is a major cause of
chronic liver diseases and a global public health problem.
Chronic HCV infection affects more than 170 million individ-
uals worldwide, of whom an estimated 20% have or will de-
velop cirrhosis. Furthermore, the annual risk of progression
towards hepatocellular carcinoma is 1% to 4% among patients
with cirrhosis (36). The combination of pegylated alpha inter-
feron (IFN-) and ribavirin is the current standard treatment
for chronic HCV infection. This treatment yields a sustained
virological response (SVR), defined by the lack of detectable
HCV RNA in serum 24 weeks after the end of therapy, in 40
to 50% of patients infected by HCV genotype 1 and in 70% to
80% of patients infected by genotype 2 or 3 (14, 17, 27). The
vast majority of patients who have an SVR are cured of the
infection.
Ribavirin (1--D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is
a guanosine analogue with a broad spectrum of activity against
DNA and RNA viruses (45). Its use in the treatment of chronic
HCV infection has been essentially empirical (36). Indeed, the
addition of ribavirin to standard or pegylated IFN- therapy
significantly increases the SVR rate over that with IFN mono-
therapy (14, 17, 27, 30, 39) and ribavirin can exert this antiviral
effect through several possible mechanisms. HCV clearance is
biphasic in responders to IFN- therapy (32, 33). The first
rapid phase, which occurs on days 1 and 2, reflects direct
inhibition of viral replication by IFN-induced antiviral effec-
tors. Mathematical modeling suggests that the second, slower
phase, which starts during the first week of administration,
reflects gradual clearance of infected cells in a context of po-
tent inhibition of viral replication (32, 33). Two recent studies
by our group suggest that ribavirin impacts both phases (4, 37).
Indeed, ribavirin monotherapy exerts significant, moderate,
early (days 2 and 3), and transient inhibition of viral replication
for approximately half of the patients, and this effect appears
to be additive with that of IFN during the first days of therapy
(37). This inhibition correlates with the concentration and
elimination half-life of ribavirin in peripheral blood (37). We
have also recently shown in a prospective randomized trial
involving patients infected by HCV genotype 1 that the prin-
cipal effect of ribavirin is to prevent breakthroughs during and
relapses after therapy for individuals who initially respond to
the pegylated IFN-–ribavirin combination (4). This suggests
that ribavirin shortens the half-life of infected cells during IFN
administration, allowing their complete elimination during the
standard 48-week treatment period in the majority of patients
who initially respond to combination therapy.
The mechanisms by which ribavirin modestly inhibits HCV
replication and prevents relapses during IFN-ribavirin com-
bination therapy are totally unknown. In vivo, ribavirin is
converted into ribavirin 5-monophosphate (RMP), ribavirin
5-diphosphate, and ribavirin 5-triphosphate (RTP) by aden-
osine kinase and possibly cytosolic 5-nucleotidase II (51).
RTP is the principal intracellular metabolite of ribavirin in
mammals, and its intracellular concentration appears to vary
according to the cell type (15, 35). A number of putative
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mechanisms have been proposed to explain the efficacy of
ribavirin against HCV infection (13, 22).
(i) Direct inhibition of HCV RNA-dependent RNA poly-
merase: RTP can be incorporated as a substrate by viral poly-
merases and can thereby inhibit RNA elongation. However,
RTP has been shown to be a weak inhibitor of a variety of viral
polymerases, including HCV RNA-dependent RNA polymer-
ase (26, 50). Given the modest antiviral effect of ribavirin
monotherapy in vivo (37), ribavirin’s direct antiviral properties
are unlikely to play a major role in HCV elimination during
combination therapy.
(ii) Inhibition of IMPDH: ribavirin 5-monophosphate,
which is a minor intracellular metabolite, competitively inhibits
both isoforms of IMP dehydrogenase (IMPDH). IMPDH in-
hibition leads to the depletion of intracellular pools of GTP
and dGTP, which are necessary for viral replication (28). IMPDH
inhibition has been reported to be the main mechanism
whereby ribavirin acts against yellow fever virus and human
parainfluenza virus 3 (23, 24). In contrast, recent results with
potent specific IMPDH inhibitors, used alone or in combina-
tion with ribavirin or IFN- for patients with chronic HCV
infection, suggest that IMPDH inhibition is not the mechanism
of ribavirin action in chronic hepatitis C (18, 31).
(iii) Immunomodulatory properties: several reports suggest
that at clinically relevant concentrations, ribavirin acts as an
immunomodulator, enhancing the production of Th1 cytokines
(interleukin-2 and gamma interferon) while suppressing Th2
cytokine production both in murine models and in humans; it
is also suggested that these properties might enhance the ac-
tivity of IFN- (6, 19, 29, 34, 46). However, the L-eniantomer
of ribavirin, levovirin, which has the same immunomodulatory
properties as ribavirin but no activity against DNA and RNA
viruses in vitro (because it cannot be converted into 5-phos-
phate derivatives (41, 47), does not share ribavirin’s clinical
properties when administered to HCV-infected patients in
combination with pegylated IFN- (38).
(iv) Mutagenic properties leading to “error catastrophe”:
the most popular hypothesis forwarded to explain the role of
ribavirin in hepatitis C therapy is its putative mutagenic po-
tential, which would lead to “error catastrophe,” i.e., disorga-
nization of the mutant distribution of the quasipecies and the
generation of nonviable viral populations. This concept was
recently introduced by Crotty et al., based on the in vitro
poliovirus model. These authors reported that ribavirin in-
duced a high frequency of genomic mutations that generated
viral progeny with reduced infectivity (7, 8). A similar effect of
high concentrations of ribavirin has been found in cell cultures
infected by RNA viruses belonging to several families, includ-
ing foot-and-mouth disease virus, Hantaan virus, West Nile
virus, and GB virus B, a member of the Flaviviridae family that
is closely related to HCV (1, 9, 16, 20, 44). In addition, ribavirin
has been reported to exert an antiviral effect related to error-
prone replication in HCV subgenomic replicons, both in Huh7
cell lines and in a full-length binary HCV replication system (5,
20, 21, 48, 53). However, error-prone replication is not the
mechanism by which ribavirin acts against arenavirus lympho-
cytic choriomeningitidis virus or the yellow fever virus, another
member of the Flaviviridae family that is related to HCV (24,
42). Conflicting results have been obtained with HCV-infected
patients receiving ribavirin (3, 25, 43, 52).
A recent study based on mathematical modeling of viral
decay in 17 patients receiving the combination of standard
IFN- and ribavirin suggested that ribavirin acts mainly by
reducing the infectivity of HCV virions produced during ther-
apy in a dose-dependent manner and that this effect may ap-
pear only when viral replication is profoundly reduced by
IFN-, thereby explaining the poor antiviral effect of ribavirin
monotherapy (10). Although mathematical modeling can only
raise hypotheses, the authors suggested that such a reduction
in virus infectivity would be in keeping with the “error catas-
trophe” hypothesis (10).
The aims of this study were to determine, by means of
thorough quasispecies sequence analysis targeting two inde-
pendent genomic regions, the following: (i) whether ribavirin
acts as an RNA mutagenic agent during treatment of patients
with chronic HCV genotype 1 infection and (ii) whether riba-
virin’s mutagenic effect (if any) occurs only in patients with
low-level virus production due to potent inhibition by coad-
ministered IFN.
MATERIALS AND METHODS
Patients. Eleven treatment-naive patients with chronic hepatitis C due to HCV
genotype 1b were randomly selected for this study among a group of patients
enrolled in a previously published randomized trial comparing viral kinetics
during exposure to various regimens of IFN- and/or ribavirin (37). The patients
were eight men and three women, and their mean age was 38  5 years (range,
31 to 52 years). All of the patients had anti-HCV antibodies in serum, detectable
HCV RNA (50 IU/ml), elevated alanine aminotransferase levels, and compen-
sated chronic liver disease. Four patients (group A) received ribavirin (Rebetol;
Schering-Plough Oncology, Kenilworth, NJ) monotherapy at a dose of 1.0 or 1.2
g/day, depending on body weight (below or above 75 kg, respectively). Four
patients (group B) received the combination of standard IFN-2b (Intron-A;
Schering-Plough Oncology) at a dose of 3 million units (MU) three times per
week, plus ribavirin, 1.0 or 1.2 g/day depending on body weight. The remaining
three patients (group C) were treated with the combination of standard IFN-2b
3 MU daily plus ribavirin 1.0 or 1.2 g/day, depending on body weight. All patients
were treated with the relevant regimen for 24 weeks, as previously reported (37).
Written informed consent was obtained from all patients, and the study was
approved by the local ethics committee (Comite´ Consultatif de Protection des
Personnes dans la Recherche Biome´dicale) in accordance with the Helsinki
Declaration.
Materials. Blood samples were taken at four time points for sequence analy-
ses: 14 days before the initiation of therapy (d14), at the initiation of therapy
(d0), on day 14 of therapy (d14) and on day 28 of therapy (d28). At each time
point and for each patient, extensive quasispecies sequence characterization (20
clones) of both the full-length nonstructural protein 3 (NS3) protease domain
and the full-length NS5A protein was performed. The rate of variation of the
consensus sequence, the frequency of mutation, the error generation rate, and
the between-sample genetic distance were calculated during the three successive
periods for each patient, i.e., between d14 and d0 (natural genetic drift in the
absence of therapy, used as the control period for each patient), between d0 and
d14 of therapy, and between d14 and d28 of therapy (when viral replication was
profoundly inhibited by IFN- in groups B and C). HCV RNA was quantified at
d14, at baseline (d0), and on days 1, 2, 3, 14, and 28 of therapy. Blood samples
for serum ribavirin assay were obtained at d0, hours 4, 8, 12, 18, 24, 30, 36, 42,
48, 62, 70, 86, and 94, and on days 14 and 28.
HCV RNA quantification. HCV RNA was quantified by using the SuperQuant
assay (National Genetics Institute, Los Angeles, CA), as previously described
(37). The detection limit of this assay is 30 IU/ml (1.5 log10 IU/ml).
Serum ribavirin assay. Serum ribavirin concentrations were determined by
means of a high-performance liquid chromatography tandem mass spectrometric
method at MDS Pharma Services (Saint-Laurent, Que´bec, Canada), as previ-
ously reported (40).
Generation of NS3 and NS5A quasispecies sequences. (i) RNA extraction. RNA
was extracted from 200 l of serum by using the High Pure viral RNA kit (Roche
Molecular Biochemicals, Mannheim, Germany), according to the manufacturer’s
instructions. The RNA pellet was eluted with 50 l of diethyl pyrocarbonate-
treated water and stored at 70°C until analysis.
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(ii) cDNA synthesis. For cDNA synthesis, 5 l of viral RNA was used with 10
pmol of antisense primers 3EAS and R3EAS for NS3 and NS5A, respectively
(Table 1). The reaction mixture (20 l) contained 50 mM Tris-HCl, pH 8.3, 75
mM KCl, 3 mM MgCl2, 10 Mm deoxynucleoside triphosphates, 100 mM dithio-
threitol, 40 U of RNase inhibitor (RNaseOUT; Invitrogen, Carlsbad, CA), and
200 U of Superscript III reverse transcriptase (Invitrogen). The reaction mixture
was incubated for 1 h at 55°C, and the enzyme was then inactivated for 15 min
at 70°C.
(iii) PCR amplification. A nested PCR method was used to amplify the
full-length NS3 protein-encoding sequence, and a seminested procedure was
used for the NS5A protein-encoding sequence. The primers used for amplifica-
tion (Table 1) were as follows: for NS3, outer primers EAS and 3EAS and inner
primers 3IS and 3IAS; for NS5A, outer primers Y4S and R3EAS and inner
primers R3ES and R3EAS. Two microliters of cDNA solution was added to the
PCR mixture containing 10 mM Tris-HCl (pH 8.5), 50 mM KCl, 2 mM MgCl2,
10 mM deoxynucleoside triphosphates, and 10 pmol of the primers in the pres-
ence of Taq Advantage DNA polymerase (BD Biosciences-Clontech, Mountain
View, CA). Amplification included initial denaturation at 95°C for 1 min, fol-
lowed by 35 cycles of denaturation at 95°C for 30 s, annealing at 53°C (NS3) or
60°C (NS5A) for 30 s, and elongation at 70°C for 30 s (NS3) or 90 s (NS5A),
followed by a final elongation step at 70°C for 12 min. The second round of PCR
included initial denaturation at 95°C for 1 min, followed by 30 cycles of dena-
turation at 95°C for 30 s, annealing at 49°C (NS3) or 55°C (NS5A) for 30 s, and
elongation at 70°C for 30 s (NS3) or 90 s (NS5A), followed by a final elongation
step at 70°C for 12 min. Amplification products (5 l) were run on 1.5% agarose
gels. The gels were stained with ethidium bromide, and DNA was viewed under
UV light.
(iv) Purification of PCR products. The PCR products were purified by using
Microcon-100 centrifugal filters (Millipore, Bedford, MA) according to the man-
ufacturer’s instructions. Amplicons were eluted in 20 l of sterile water and
stored at 20°C until analysis.
(v) Cloning and sequencing. Purified products were cloned into the pCR4-
TOPO vector, using the TOPO TA cloning kit (Invitrogen) according to the
manufacturer’s protocol. Recombinant plasmids were transformed in Escherichia
coli TOP10 competent cells, and transformants were grown on ampicillin plates.
Cloned DNAs were PCR amplified with the M13 plasmid universal primers and
Pfu DNA polymerase (Qbiogene, Irvine, CA). The amplified clones were puri-
fied by means of the Wizard SV96 PCR Clean-Up system (Promega, Madison,
WI) according to the manufacturer’s protocol. Twenty clones per time point per
patient were sequenced with the Big-Dye Terminator Cycle v3.1 sequencing kit
on the ABI 3100 sequencer (Applied Biosystems, Foster City, CA), according to
the manufacturer’s protocol. Both DNA strands were sequenced with the M13
universal primers.
NS3 and NS5A sequence analysis and statistical analysis. The generated
sequences were aligned by using CLUSTAL W software (49). For each sample
from each patient, the consensus nucleotide sequence of the quasispecies was
deduced and its rate of variation was determined by counting the number of
nucleotide substitutions at each 14-day interval, dividing it by the length of the
sequenced fragment, and multiplying it by 26 to give the variation per site per
year.
The error generation rate was calculated by measuring the number of nucle-
otide substitutions in all of the sequenced clones relative to the consensus
sequence at the previous time point divided by the total number of sequenced
nucleotides over each 14-day interval (d14 to d0, d0 to d14, and d14 to d28) for
each patient. This number was multiplied by 26 to obtain the error generation
rate, expressed as the number of substitutions per site per year.
The mutation frequency was determined as the total number of nucleotide
substitutions (in the 20 clones analyzed at each time point) relative to the
consensus sequence at the same time point, divided by the total number of
sequenced nucleotides. The normalized Shannon entropy was calculated as
	i(pi ln pi)/ln N, where pi represents the frequency of each sequence in the
quasispecies and N is the total number of sequences analyzed. The between-
sample genetic distances were calculated on the basis of distances between pairs
of sequences generated at 14-day intervals.
Statistical calculations were carried out by using the descriptive statistics,
linear regression, hypothesis test, and analysis-of-variance (ANOVA) packages
for Mathematica 5.0 (Wolfram Research).
Nucleotide sequence accession numbers. Sequence data from this article have
been deposited in GenBank under accession numbers AM400248 to AM400838
and AM401639 to AM402384.
RESULTS
Concentrations of ribavirin in serum. Figure 1 shows the
kinetics of serum ribavirin concentrations for the patients re-
ceiving ribavirin monotherapy (group A) (Fig. 1A), those re-
ceiving a combination of IFN- three times per week and
ribavirin (group B) (Fig. 1B), and those receiving a combina-
tion of IFN- daily and ribavirin (group C) (Fig. 1C). High
ribavirin concentrations in serum were achieved within a few
hours after the first oral intake, but the levels fluctuated during
the first days of administration. A plateau was reached by day
14 in all cases.
Dynamics of viral replication. As shown in Fig. 2A, patients
in group A (ribavirin monotherapy) had an early, moderate,
and transient fall in viral replication, as previously reported
(37). Their viral load fell by 0.35 to 1.55 log10 IU/ml but
returned to near-baseline levels by day 14. None of these pa-
tients experienced a second slope of viral decline.
In group B (IFN- three times per week plus ribavirin) (Fig.
2B) and in group C (IFN- daily plus ribavirin) (Fig. 2C), HCV
RNA showed a typical biphasic decline. The initial, rapid de-
cline was observed on day 1 after the first IFN- dose. It
ranged from 0.22 to 2.13 log10 HCV RNA IU/ml. It was
followed by a reincrease in viral replication on day 2 in group
B before the second IFN- injection (Fig. 2B) but not for
group C patients, who received daily IFN- injections (Fig.
2C). A significant second slope of viral decline was observed
for all patients in these two groups and was more pronounced
TABLE 1. Primers used for PCR amplification of full-length NS3 and NS5A protein-encoding sequences of HCV genotype 1ba
Target Primer description Primer name Sequence Nucleotide positions
NS3 Outer
Sense 3ES 5-TGTGGGGACATCATCTTGG-3 3224–3306
Antisense 3EAS 5-ACTTTGGTGCTCTTGCCGCT-3 4029–4048
Inner
Sense 3IS 5-GAGATACTTTTGGGACCGGCT-3 3354–3374
Antisense 3IAS 5-GGAGATGAGTTGTCTGTGAA-3 3957–3976
NS5A Outer
Sense Y4S 5-GTGCAGTGGATGAAYCGGCTGATAGC-3 6066–6091
Antisense R3EAS 5-GTGGTGACGCAGCAAAGAGT-3 7669–7688
Inner
Sense R3ES 5-CAGCCTTACCATCACCCAGC-3 6176–6195
a Primer positions are given according to numbering of the HCV-J genotype 1b prototype sequence, accession number D90208.
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in group C than in group B (Fig. 2B and C). In all cases and in
both groups, the sample at week 28 was the last in which HCV
RNA was detectable (i.e., HCV RNA was undetectable in the
next sample, 4 weeks later).
Clonal analysis of HCV quasispecies. Overall, 1,600 quasi-
species variant sequences were generated, including 20 clones
per patient of the full-length NS3 protease- and NS5A-encod-
ing regions at 4 time points for the 8 patients in groups A and
B and at 3 time points for the 3 patients in group C. On day 28,
for the group C patients, who received daily IFN- and riba-
virin and had a more rapid HCV RNA decline, NS3 could not
be PCR amplified in one case, NS5A in another case, and both
in the remaining case, owing to low HCV RNA levels. In order
to determine whether our sampling was biased by a limiting-
dilution effect, especially in the samples with a very low HCV
RNA content, which would have hidden a possible mutagenic
effect of ribavirin, all templates were diluted 1/10 and the same
PCR amplification procedures were applied. All samples gave
visible PCR bands in both regions, except for two samples with
a very low HCV RNA content at D28 for patients receiving the
combination of IFN- and ribavirin. This experiment ruled out
a sampling bias.
To determine whether the analysis of 20 clones per time
point was sufficient to evaluate total viral populations, we de-
termined the mean, standard deviation (SD), standard error of
the mean (SEM), and 95% confidence intervals (CI) for the
mutation frequency in both genomic regions analyzed (Table
2). As shown in Table 2, the SEM values were on average 1
order of magnitude lower than the means, suggesting that the
sample size was sufficient to ensure excellent accuracy.
FIG. 1. Dynamics of serum ribavirin concentrations (in log ng/ml) during 28 days of oral administration for four patients receiving ribavirin
monotherapy, 1.0 to 1.2 g/day according to body weight (group A), for four patients receiving a combination of standard IFN-, 3 MU three times
per week, plus ribavirin (group B), and for three patients receiving a combination of IFN-, 3 MU daily, plus ribavirin (group C).
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Shannon entropy. Shannon entropy is the probability that a
given sequence or cluster of sequences will appear at a given
time point. It gives a measure of the genetic diversity of a viral
quasispecies at a given time point. Table 3 shows the Shannon
entropy at every time point in the NS3 and NS5A coding
regions for samples from the 11 patients. The values were very
high at baseline, so it was not possible to detect an increase
during therapy.
Mutation frequencies. To determine whether the mutation
frequency increased during ribavirin administration, the mean
mutation frequencies at successive time points were compared
by using Student’s t test. As shown in Table 4, the vast majority
of comparisons showed no significant differences between the
viral mutation frequencies at consecutive time points for the 11
patients. The few significant differences were most often neg-
ative, indicating a trend towards a fall in the average mutation
frequency over time. These occasional, randomly distributed
significant differences could in fact have been due to chance,
given the large number of statistical comparisons performed.
In order to confirm the lack of an increase in mutation
frequency during treatment, we performed linear regression
analysis of the differences in mutation frequencies at each
14-day interval for each patient. The results showed that the
accumulation of mutations did not accelerate significantly for
samples from any of the patients when ribavirin was adminis-
tered alone or in combination with IFN-.
Additional regression analyses focused on the average dif-
ference in mean mutation frequencies for each 14-day period,
pooling the results for the 11 patients, and for each treatment
group. In the NS3 region, the P values for the slopes of the
straight lines best fitting the data were always higher than 0.05
(data not shown), confirming the lack of acceleration of mu-
tation accumulation during ribavirin administration with or
without IFN-. The P values were also nonsignificant for the
NS5A region.
In a global analysis based on ANOVA, three or four groups
of values were compared. The difference in the mean mutation
frequencies for the d14-to-d0 interval for samples from all
patients was used as the control. It was compared with the
differences in mean mutation frequencies in each treatment
group for the d0-to-d14 interval on the one hand and for the
d14-to-d28 interval on the other hand (group C could not be
included in this last comparison because PCR amplification on
d28 was possible with only one patient). This analysis showed
that there was no significant difference in the mutation fre-
quencies between the treatment groups or in either group
relative to the control during either interval.
Error generation rates and between-sample genetic dis-
tances. In order to complete the study of the diversity of HCV
quasispecies during treatment with ribavirin, two additional
parameters, the error generation rate and the between-sample
genetic distance, were analyzed.
The error generation rate was determined as the mutation
frequency relative to the consensus sequence at the previous
time point, with a correction factor to obtain the rate per year
(Tables 5 and 6). The error generation rate did not increase
with ribavirin administration for any of the patients (regression
analysis). Likewise, ANOVA showed no significant difference
in the error generation rates between the controls (d14 to
d0) and the treated groups at either time interval (d0 to d14 or
d14 to d28).
The mean between-sample genetic distances were calculated
on the basis of the distances between pairs of sequences ob-
tained at 14-day intervals (Tables 5 and 6). Regression analysis
FIG. 2. Dynamics of viral replication during the first 28 days of therapy for the four patients receiving ribavirin monotherapy, 1.0 to 1.2 g/day
according to body weight (group A), for the four patients receiving a combination of standard IFN-, 3 MU three times per week, plus ribavirin
(group B), and for the three patients receiving a combination of IFN-, 3 MU daily, plus ribavirin (group C). The viral kinetics are shown as log
HCV RNA reductions relative to baseline (represented by the 0 line). No patient from group A became HCV RNA negative at any time point
of therapy, whereas in groups B and C, the sample at day 28 was the last sample with detectable HCV RNA.
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0.001–0.006
0.005

0.004
0.0010
0.003–0.007
0.002

0.001
0.0004
0.003–0.007
0.004

0.003
0.0009
0.002–0.006
8
0.003

0.002
0.0005
0.002–0.004
0.004

0.003
0.0007
0.003–0.005
0.002

0.001
0.0004
0.003–0.005
0.002

0.002
0.0005
0.001–0.003
9
0.006

0.003
0.0008
0.004–0.007
0.006

0.003
0.0006
0.005–0.007
0.001

0.001
0.0003
0.005–0.007
N
A
N
A
N
A
10
0.005

0.006
0.0018
0.001–0.009
0.002

0.002
0.0005
0.001–0.003
0.004

0.004
0.0010
0.001–0.003
N
A
N
A
N
A
11
0.003

0.003
0.0007
0.002–0.005
0.003

0.002
0.0005
0.002–0.004
0.004

0.002
0.0005
0.002–0.004
0.002

0.001
0.0004
0.001–0.003
N
S5A
1
0.005

0.002
0.0004
0.004–0.006
0.005

0.003
0.0008
0.004–0.007
0.003

0.004
0.0010
0.001–0.005
0.004

0.002
0.0004
0.003–0.005
2
0.002

0.001
0.0003
0.002–0.003
0.006

0.006
0.0013
0.004–0.009
0.006

0.003
0.0008
0.004–0.007
0.003

0.002
0.0003
0.002–0.004
3
0.004

0.004
0.0008
0.003–0.006
0.005

0.004
0.0009
0.003–0.007
0.005

0.004
0.0009
0.004–0.007
0.004

0.002
0.0005
0.003–0.006
4
0.002

0.001
0.0003
0.001–0.002
0.002

0.003
0.0006
0.001–0.003
0.004

0.004
0.0004
0.002–0.003
0.010

0.006
0.0014
0.007–0.013
5
0.003

0.001
0.0002
0.003–0.004
0.006

0.002
0.0005
0.005–0.007
0.002

0.002
0.0005
0.001–0.004
0.002

0.001
0.0003
0.001–0.002
6
0.004

0.003
0.0007
0.003–0.005
0.004

0.003
0.0007
0.003–0.005
0.004

0.003
0.0008
0.002–0.006
0.005

0.003
0.0008
0.003–0.007
7
0.007

0.004
0.0010
0.005–0.009
0.007

0.003
0.0007
0.006–0.008
0.006

0.002
0.0005
0.005–0.007
0.008

0.004
0.0010
0.006–0.010
8
0.006

0.004
0.0010
0.003–0.008
0.005

0.005
0.0012
0.003–0.008
0.002

0.001
0.0003
0.002–0.003
0.002

0.001
0.0002
0.002–0.003
9
0.007

0.002
0.0005
0.006–0.008
0.004

0.001
0.0003
0.003–0.005
0.006

0.003
0.0007
0.005–0.008
N
A
N
A
N
A
10
0.003

0.002
0.0004
0.002–0.004
0.001

0.001
0.0002
0.001–0.002
0.003

0.001
0.0002
0.002–0.003
0.002

0.001
0.0003
0.001–0.002
11
0.006

0.003
0.0007
0.004–0.007
0.006

0.002
0.0005
0.005–0.007
0.004

0.002
0.0004
0.003–0.005
N
A
N
A
N
A
a
M
utation
frequencies
are
expressed
as
num
ber
of
substitutions
per
nucleotide.N
A
,not
applicable.
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showed no linear increase in the genetic distances with ribavi-
rin administration, and the differences in means at consecutive
time points were not significant for samples from the patients
in a given group, except for one patient (patient 4), for whom
a trend towards an increase in the between-sample genetic
distances in the NS5A region was shown. Samples from this
patient also showed a significant difference in the mutation
frequencies in the same region between days 14 and 28.
A similar global ANOVA analysis of mutation frequencies
and error generation rates was performed for the between-sample
genetic distances and showed no difference between the three
treatment groups or with the controls, either between d0 and d14
or between d14 and d28 (data not shown).
Rate of variation of the consensus sequence. The rate of
variation of the consensus sequence was also calculated in
order to determine if treatment with ribavirin affects the fixa-
tion of mutations in the HCV genome, as would happen if the
drug induced the selection of specific nucleotide substitutions.
The results are shown in Tables 5 and 6 for the 11 patients.
Regression analyses were performed with the differences in the
rate of variation of the consensus sequence at 14-day intervals
for samples from the 11 patients in the NS3 and NS5A coding
regions. The P values for the slopes of the straight lines best
fitted to the data indicated no sustained linear trend towards
an increase in the fixation of mutations on ribavirin therapy
(data not shown). The differences in the mean values at con-
secutive time points for patients belonging to a given treatment
group were also not significant. A similar global ANOVA anal-
ysis of mutation frequencies was performed with this parame-
ter and showed no significant difference between the three
treatment groups or with the controls, either between d0 and
d14 or between d14 and d28.
DISCUSSION
We conducted an extensive sequence-based analysis of two
independent genomic regions of HCV, taking into consider-
ation the quasispecies distribution of the viral genomes, in
order to test in vivo the hypothesis that ribavirin administration
accelerates the accumulation of mutations in the HCV genome
and that this acceleration occurs only when HCV replication is
profoundly inhibited by coadministered IFN-. The spontane-
ous error generation rates observed for our three groups of
patients prior to therapy, reflecting natural genetic drift, were
higher than the known error rate of the HCV RNA-dependent
RNA polymerase (11, 12). This was probably due to the fact
that they were measured over a short period of time (14 days)
and finally expressed per year.
Ribavirin monotherapy did not increase the mutation fre-
quency, the error generation rate, or the between-sample ge-
netic distances during either the first or the second 14-day
period with treatment. Likewise, the accumulation of nucleo-
tide substitutions did not accelerate relative to that in the
pretreatment period during combination therapy with ribavirin
and IFN- at a dose of 3 MU given either daily or three times
per week. Finally, these parameters did not increase between
days 14 and 28 of therapy, when HCV replication was pro-
TABLE 3. Shannon entropy in viral NS3 and NS5A coding regions
at each time point for samples from the 11 patients
Patient
Shannon entropya
NS3 NS5A
d14 d0 d14 d28 d14 d0 d14 d28
1 0.95 0.93 0.95 0.93 0.97 0.97 1.00 0.98
2 0.91 0.91 0.96 0.88 1.00 0.93 1.00 1.00
3 0.96 0.92 0.93 0.89 0.95 0.98 0.95 1.00
4 0.90 0.89 0.97 0.97 0.93 0.93 0.92 0.98
5 0.91 0.95 0.92 0.96 0.90 0.95 0.86 1.00
6 0.98 0.90 0.95 0.94 1.00 1.00 1.00 0.97
7 0.95 0.94 0.96 0.84 0.95 0.98 0.98 0.98
8 0.95 0.98 0.95 0.95 1.00 0.97 0.98 1.00
9 0.97 0.95 0.86 NAb 0.98 1.00 1.00 NA
10 0.91 0.93 0.97 NA 0.90 0.95 1.00 0.98
11 0.97 0.95 0.95 0.96 0.95 1.00 0.98 NA
a For an explanation, see Materials and Methods.
b NA, not applicable.
TABLE 4. Comparison of mean viral mutation frequencies at two successive time pointsa
Patient
Comparison of mutation frequencies for:
NS3 NS5A
d0 vs d14 d14 vs d0 d28 vs d14 d0 vs d14 d14 vs d0 d28 vs d14
Difference
of means P value
Difference
of means P value
Difference
of means P value
Difference
of means P value
Difference
of means P value
Difference
of means P value
1 0.002 0.0006 0.000 0.47 0.000 0.44 0.000 0.36 0.002 0.03 0.001 0.14
2 0.002 0.21 0.009 
0.001 0.002 0.04 0.004 0.004 0.000 0.39 0.003 0.002
3 0.001 0.30 0.000 0.50 0.002 0.13 0.001 0.34 0.000 0.36 0.001 0.19
4 0.002 0.005 0.001 0.18 0.002 0.10 0.000 0.38 0.000 0.30 0.007 
0.001
5 0.002 0.052 0.001 0.12 0.000 0.41 0.002 
0.001 0.003 
0.001 0.000 0.10
6 0.000 0.49 0.002 0.003 0.000 0.30 0.000 0.44 0.000 0.49 0.001 0.20
7 0.002 0.16 0.003 0.01 0.002 0.04 0.000 0.40 0.001 0.13 0.002 0.05
8 0.001 0.11 0.002 0.009 0.000 0.34 0.000 0.41 0.003 0.002 0.000 0.46
9 0.000 0.32 0.005 0.0001 NAb NA 0.003 
0.001 0.002 0.008 NA NA
10 0.003 0.06 0.002 0.10 NA NA 0.001 0.001 0.002 
0.001 0.001 0.001
11 0.000 0.29 0.001 0.08 0.002 0.002 0.000 0.43 0.002 
0.001 0.001 0.001
a Mutation frequency is defined as the number of substitutions per nucleotide. The difference in means and the P value (Student’s t test) are given for each 14-day
interval for viral NS3 and NS5A coding regions for samples from 11 patients.
b NA, not applicable.
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foundly inhibited by IFN administration (day 28 corresponded
to the last sample containing detectable HCV RNA for pa-
tients receiving combination therapy). Our painstaking statis-
tical analysis showed no common trend towards an accelera-
tion of the accumulation of mutations during ribavirin
monotherapy or during IFN-ribavirin combination therapy
even when viral replication was profoundly inhibited by IFN-.
These results show that ribavirin does not act as an RNA
mutagen in vivo, at least at the weight-based doses used for
therapy and despite relatively high concentrations in plasma
(the steady-state ribavirin concentration in peripheral blood
was reached on day 14).
Although we examined only viruses circulating in peripheral
blood, these viral populations closely reflect virions produced
in the liver, since the average half-life of free HCV virions in
the general circulation is of the order of 2.7 h and about 1012
virions are produced and cleared daily (32). In addition, there
is no clear reason why viruses undergoing random nucleotide
substitutions under the putative mutagenic effect of ribavirin
should be preferentially sequestered in the liver while nonmu-
tated virions would be normally excreted and released into
peripheral blood.
Our findings therefore show that ribavirin has no noteworthy
mutagenic effect in vivo, even when HCV replication is
strongly inhibited by IFN administration. This is important in
light of the recent suggestion by Dixit et al., based on mathe-
matical modeling of viral decay in patients receiving the IFN-
ribavirin combination, that the main action of ribavirin is to
render HCV virions less infectious and that this property is
revealed only when HCV replication is profoundly inhibited by
the antiviral properties of coadministered IFN (10). If this is so
(and it has not yet been experimentally confirmed), our results
do not suggest that the underlying mechanism is error catas-
trophe due to accelerated mutagenesis.
TABLE 5. Error generation rates, between-sample genetic distances, and rates of variation of consensus sequences between
two successive time points in the NS3 region
Patient
Comparison of samples
d0 vs d14 d14 vs d0 d28 vs d14
EGRa Between-samplegenetic distance
Rate of variation
of consensus
sequenceb
EGR Between-samplegenetic distance
Rate of variation
of consensus
sequence
EGR Between-samplegenetic distance
Rate of variation
of consensus
sequence
1 0.2586 0.0135 0.1914 0.1365 0.0094 0.0478 0.1149 0.0086 0.0478
2 0.5315 0.0226 0.3832 0.2777 0.0190 0.2392 0.4692 0.0252 0.4789
3 0.1915 0.0123 0.0000 0.2131 0.0133 0.0000 0.1101 0.0123 0.0478
4 0.2825 0.0135 0.1914 0.0982 0.0094 0.0000 0.1843 0.0129 0.0478
5 0.1413 0.0085 0.0957 0.0407 0.0065 0.0000 0.2801 0.0140 0.2392
6 0.1317 0.0084 0.0478 0.1628 0.0098 0.0000 0.1796 0.0129 0.1435
7 0.5842 0.0283 0.5746 0.1867 0.0111 0.1435 0.5099 0.0266 0.5268
8 0.1221 0.0081 0.0000 0.1820 0.0133 0.1435 0.1772 0.0106 0.1435
9 0.1676 0.0132 0.0000 0.0981 0.0106 0.0957 NAc NA NA
10 0.0287 0.0096 0.0000 0.1149 0.0080 0.0478 NA NA NA
11 0.0766 0.0078 0.0000 0.1221 0.0083 0.0000 0.1389 0.0112 0.0957
a EGR, error generation rate (no. of nucleotides/site/year).
b Rate of variation of consensus sequence is expressed as no. of nucleotides/site/year.
c NA, not applicable.
TABLE 6. Error generation rates, between-sample genetic distances, and rates of variation of consensus sequences between
two successive time points in NS5A region
Patient
no.
Comparison of samples
d0 vs d14 d14 vs d0 d28 vs d14
EGRa Between-samplegenetic distance
Rate of variation
of consensus
sequenceb
EGR Between-samplegenetic distance
Rate of variation
of consensus
sequence
EGR Between-samplegenetic distance
Rate of variation
of consensus
sequence
1 0.1284 0.0097 0.0187 0.0595 0.0079 0.0187 0.1227 0.0069 0.0187
2 0.2947 0.0160 0.2132 0.1638 0.0143 0.0582 0.1057 0.0099 0.0192
3 0.3611 0.0206 0.0905 0.3543 0.0229 0.0452 0.3160 0.0228 0.0452
4 0.6139 0.0264 0.5866 0.7042 0.0290 0.6318 0.6319 0.0311 0.1804
5 0.1551 0.0092 0.0192 0.0756 0.0105 0.0775 0.1861 0.0089 0.1357
6 0.1076 0.0084 0.0000 0.1241 0.0084 0.0192 0.1173 0.0093 0.0000
7 0.2123 0.0132 0.0775 0.1832 0.0124 0.0967 0.2259 0.0131 0.0000
8 0.1103 0.0102 0.0000 0.1006 0.0094 0.0385 0.1993 0.0112 0.1544
9 0.1619 0.0124 0.1160 0.2540 0.0124 0.1160 NAc NA NA
10 0.0950 0.0071 0.0775 0.1483 0.0070 0.1160 0.3529 0.0157 0.03448
11 0.3122 0.0135 0.1550 0.1338 0.0112 0.0385 NA NA NA
a EGR, error generation rate (no. of nucleotides/site/year).
b Rate of variation of consensus sequence is expressed as no. of nucleotides/site/year.
c NA, not applicable.
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The very high concentrations of ribavirin used in in vitro
studies in which the mutagenic effect of ribavirin was observed
could explain the discrepancy with our results obtained in the
clinical setting. Indeed, the doses used in vitro were generally
near toxic (50 to 1,000 M, doses that cannot be achieved
intracellularly during human therapy), and mutagenesis ap-
peared to be concentration dependent. Interestingly, the riba-
virin concentration required to achieve a significant antiviral
effect differed between HCV-unrelated viruses (100 to 1,000
M), GB virus B (100 to 200 M), and subgenomic HCV
replicons (50 to 400 M) (1, 5, 8, 16, 20, 21, 48). Different cell
types might have different capacities to convert ribavirin into
RTP, and different rates of division (primary hepatocytes ver-
sus cultured cells) could influence the size of the intracellular
GTP pool and the affinity of the polymerase for ribavirin. In
any case, the ribavirin concentrations achieved with these mod-
els were substantially higher than those achieved intracellularly
during human therapeutics (the latter cannot easily be mea-
sured, owing to the lack of an appropriate assay).
Our results differ from those of Asahina et al. (3), who
reported a significantly higher rate of HCV mutations during 4
weeks of ribavirin monotherapy than prior to therapy (3). That
study was based on direct sequence analysis; however, the
approach is subject to misinterpretation of mixed or ambigu-
ous profiles. In contrast, we used extensive quasispecies anal-
ysis to evaluate any possible change in the diversity of the
population that could result from an increase of the virus
polymerase error rate. In addition, Asahina’s study suffered
from a major methodological bias, since the pretreatment con-
trol period was variable (6 months on average; range, 2 to 48
months), whereas ribavirin monotherapy always lasted 4 weeks
(3). We have found that error generation rates bear a negative
relation to the interval between the two time points used to
calculate them (Chevaliez and Pawlotsky, unpublished obser-
vation). This is due to the increase in the numerator (duration
of the interval) in a context of slow spontaneous and random
accumulation of mutations and to the use of short target se-
quences. As a result, the error generation rates during the
pretreatment period in Asahina’s study were probably substan-
tially underestimated. In order to avoid this bias, we chose to
use the same duration (14 days) for each of the three studied
intervals, comprising the pretreatment period (control period),
the first 14 days of treatment, and the second 14-day period,
during which patients receiving combination therapy had vari-
able levels of inhibition of HCV replication by IFN-. With
this approach we were able to show that mutation accumula-
tion in two independent HCV genomic regions did not accel-
erate during treatment with ribavirin either alone or combined
with IFN-. These results are in keeping with preliminary
studies which found no difference in error generation rates
between patients receiving ribavirin monotherapy, IFN-
monotherapy, or IFN-ribavirin combinations (2, 43, 52).
In conclusion, our study, based on a robust methodology,
strongly undermines the hypothesis whereby ribavirin acts as
an HCV mutagen in vivo, leading to error catastrophe and viral
eradication when combined with IFN. This is not altogether
surprising, since the hypothesis was based on the use of in vitro
models and near-toxic ribavirin concentrations. Unfortunately,
the mechanism of ribavirin action remains as elusive as ever. A
direct antiviral effect does not appear to play a major role, and
neither does IMPDH inhibition (18, 28, 31, 37). A break-
through in our understanding of how ribavirin works is ur-
gently needed in order to develop drugs that mimic the anti-
viral properties of ribavirin without inducing severe hemolytic
anemia, an adverse effect that often leads to dose reductions or
withdrawal and subsequent treatment failure.
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